Elixir Medical to Present at J.P. Morgan Healthcare Conference

J.P. Morgan Healthcare Conference 2015

SUNNYVALE, Calif.--()--Elixir Medical Corporation, a privately held medical company is scheduled to participate in the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Motasim Sirhan, President and Chief Executive Officer, will make a presentation about the company on Tuesday, January 13, 2015 at 8:30 a.m. PST (11:30 a.m. EST) in the Elizabethan C at the Westin St. Francis.

About Elixir Medical

Elixir Medical Corporation develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide patients with innovative treatment solutions. The company was founded in 2005, and is based in Sunnyvale, California.

Elixir’s initial area of focus is coronary vascular intervention, with a broad portfolio of products leveraging Elixir’s unique pharmaceutical, drug release, stent platforms, and scaffold technologies:

  • DESolve® 100: CE Mark-approved and the world’s first fully resorbable drug eluting scaffold system with a dramatically thinner strut profile of 100µm (one hundred microns)
  • DESolve®: CE Mark-approved fully resorbable drug eluting scaffold system
  • DESyne BD®: CE Mark-approved degradable coating drug eluting stent system
  • DESyne®: CE Mark-approved durable polymer coating drug eluting stent system

Elixir is also developing resorbable scaffolds for peripheral vascular indications. The peripheral programs are currently in the preclinical phase.

For more information on the company and its products, please visit www.elixirmedical.com.


Elixir Medical
Vinayak Bhat, Ph.D., 408-636-2006

Release Summary

Elixir Medical to present at the JP Morgan Annual Health Care Conference on Tues., Jan 13 2015 at 8:30a in San Francisco. DESolve 100, DESolve, DESyne BD and DESyne to be discussed.


Elixir Medical
Vinayak Bhat, Ph.D., 408-636-2006